PTPRC and Alzheimer disease: In this study, cultured AD-MSCs from the third passage indicated expression of CD90 (98.23 ± 2.31), CD44 (98.27 ± 1.86), CD29 (80.93 ± 7.01%), CD31 (1.20 ± 0.58), CD11b (0.43 ± 0.25), and CD45 (0.40 ± 0.18%, Figure 3E).